The science and practice of bone health in oncology: Managing bone loss and metastasis in patients with solid tumors

Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman, Matthew R. Smith

Research output: Contribution to journalReview articlepeer-review

69 Scopus citations

Abstract

Cancer and its treatment can compromise bone health, leading to fracture, pain, loss of mobility, and hypercalcemia of malignancy. Bone metastasis occurs frequently in advanced prostate and breast cancers, and bony manifestations are commonplace in multiple myeloma. Osteoporosis and osteopenia may be consequences of androgen-deprivation therapy for prostate cancer, aromatase inhibition for breast cancer, or chemotherapy-induced ovarian failure. Osteoporotic bone loss and bone metastasis ultimately share a pathophysiologic pathway that stimulates bone resorption by increasing the formation and activity of osteoclasts. Important mediators of pathologic bone metabolism include substances produced by osteoblasts, such as RANKL, the receptor activator of nuclear factor kappa B ligand, which spurs osteoclast differentiation from myeloid cells. Available therapies are targeted to various steps in cascade of bone metastasis.

Original languageEnglish (US)
Pages (from-to)S1-S29
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume7
Issue numberSUPPL. 7
DOIs
StatePublished - 2009

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'The science and practice of bone health in oncology: Managing bone loss and metastasis in patients with solid tumors'. Together they form a unique fingerprint.

Cite this